Michael Looby

542 total citations
23 papers, 432 citations indexed

About

Michael Looby is a scholar working on Pharmacology, Statistics and Probability and Oncology. According to data from OpenAlex, Michael Looby has authored 23 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 6 papers in Statistics and Probability and 5 papers in Oncology. Recurrent topics in Michael Looby's work include Statistical Methods in Clinical Trials (6 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). Michael Looby is often cited by papers focused on Statistical Methods in Clinical Trials (6 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). Michael Looby collaborates with scholars based in Switzerland, United States and Germany. Michael Looby's co-authors include Willi Weber, Christian Bartels, Romain Séchaud, Didier Renard, Jürgen Brockmöller, Ivar Roots, H.-H. Neumayer, Joachim Köchling, G Kewitz and Benjamin Krämer and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Michael Looby

22 papers receiving 418 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Looby Switzerland 12 134 121 116 72 59 23 432
Marshall Sack United States 11 76 0.6× 122 1.0× 44 0.4× 23 0.3× 39 0.7× 12 517
David Han United States 13 59 0.4× 104 0.9× 118 1.0× 28 0.4× 54 0.9× 28 557
Satoru Nagashima Japan 15 40 0.3× 134 1.1× 60 0.5× 41 0.6× 66 1.1× 41 565
Dinko Rekić Sweden 11 143 1.1× 23 0.2× 63 0.5× 57 0.8× 78 1.3× 29 451
Madelé van Dyk Australia 15 103 0.8× 87 0.7× 50 0.4× 55 0.8× 197 3.3× 35 682
Glynn Morrish Australia 6 31 0.2× 72 0.6× 50 0.4× 53 0.7× 49 0.8× 12 351
François A. Leblond Canada 13 46 0.3× 45 0.4× 63 0.5× 115 1.6× 125 2.1× 22 632
Melih O. Babaoğlu Türkiye 13 58 0.4× 58 0.5× 43 0.4× 142 2.0× 134 2.3× 43 509
Gunnar Ekenved Sweden 14 128 1.0× 103 0.9× 42 0.4× 95 1.3× 121 2.1× 25 935
Amanda Freeman United States 11 97 0.7× 188 1.6× 113 1.0× 73 1.0× 287 4.9× 13 748

Countries citing papers authored by Michael Looby

Since Specialization
Citations

This map shows the geographic impact of Michael Looby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Looby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Looby more than expected).

Fields of papers citing papers by Michael Looby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Looby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Looby. The network helps show where Michael Looby may publish in the future.

Co-authorship network of co-authors of Michael Looby

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Looby. A scholar is included among the top collaborators of Michael Looby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Looby. Michael Looby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Looby, Michael, Kristine A. Donovan, Rhys Lewis, et al.. (2025). Physical fitness and body composition assessments in advanced cancer patients undergoing exenterative surgery – A pilot cohort study. Colorectal Disease. 27(11). e70298–e70298.
2.
Akacha, Mouna, Christian Bartels, Björn Bornkamp, et al.. (2021). Estimands—What they are and why they are important for pharmacometricians. CPT Pharmacometrics & Systems Pharmacology. 10(4). 279–282. 8 indexed citations
3.
Sander, Oliver, Baldur Magnusson, Astrid Jullion, et al.. (2021). A framework to guide dose & regimen strategy for clinical drug development. CPT Pharmacometrics & Systems Pharmacology. 10(11). 1276–1280. 10 indexed citations
4.
Bretz, Frank, et al.. (2018). Key Aspects of Modern, Quantitative Drug Development. Statistics in Biosciences. 10(2). 283–296. 2 indexed citations
5.
Stein, Andrew M. & Michael Looby. (2018). Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive Performance. CPT Pharmacometrics & Systems Pharmacology. 7(8). 487–489. 10 indexed citations
6.
Bartels, Christian, et al.. (2013). Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. British Journal of Clinical Pharmacology. 76(6). 868–879. 41 indexed citations
7.
Overend, Tim, Didier Renard, M.R.J. Gibbs, et al.. (2012). A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulmonary Medicine. 12(1). 74–74. 30 indexed citations
8.
Wu, Kai, François Mercier, Olivier David, Robert Schmouder, & Michael Looby. (2011). Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants. The Journal of Clinical Pharmacology. 52(7). 1054–1068. 14 indexed citations
9.
Renard, Didier, Michael Looby, Benjamin Krämer, et al.. (2011). Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respiratory Research. 12(1). 54–54. 36 indexed citations
10.
Wu, Kai, et al.. (2010). Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients. Journal of Pharmacokinetics and Pharmacodynamics. 38(1). 105–119. 24 indexed citations
11.
Ogungbenro, Kayode, et al.. (2009). Population pharmacokinetics and optimal design of paediatric studies for famciclovir. British Journal of Clinical Pharmacology. 68(4). 546–560. 21 indexed citations
12.
Scott, Graham, Christiane Rordorf, Christine Reynolds, et al.. (2004). Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid. Clinical Pharmacokinetics. 43(7). 467–478. 55 indexed citations
13.
Looby, Michael, et al.. (1997). Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit. Cancer Chemotherapy and Pharmacology. 39(6). 554–556. 8 indexed citations
14.
Looby, Michael, et al.. (1996). Pharmacokinetics of Trapidil in Patients with Chronic Liver Disease. The Journal of Clinical Pharmacology. 36(10). 897–902. 3 indexed citations
15.
Looby, Michael & Michael Weiß. (1995). Accuracy of noncompartmental pharmacokinetic parameters estimated from bolus injection and steady-state infusion data. Journal of Pharmacokinetics and Biopharmaceutics. 23(6). 635–649. 2 indexed citations
16.
Keller, Frieder, et al.. (1994). Vancomycin Dosing in Haemodialysis Patients and Bayesian Estimate of Individual Pharmacokinetic Parameters. The International Journal of Artificial Organs. 17(1). 19–26. 9 indexed citations
17.
Weber, Willi, et al.. (1993). Population kinetics of gentamicin in neonates. European Journal of Clinical Pharmacology. 44(S1). S23–S25. 35 indexed citations
18.
Weber, Willi, Michael Looby, & Jürgen Brockmöller. (1992). Evaluation of Hepatic Function Using the Pharmacokinetics of a Therapeutically Administered Drug. Clinical Pharmacokinetics. 23(1). 69–83. 3 indexed citations
19.
Weber, Willi, et al.. (1991). System analysis in multiple dose kinetics: Evidence for saturable tubular reabsorption of the organic cationN 1-methylnicotinamide in humans. Journal of Pharmacokinetics and Biopharmaceutics. 19(5). 553–574. 22 indexed citations
20.
Weber, Willi, et al.. (1990). Nonlinear kinetics of the thiamine cation in humans: Saturation of nonrenal clearance and tubular reabsorption. Journal of Pharmacokinetics and Biopharmaceutics. 18(6). 501–523. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marshall Sack Breakdown of academic impact, for papers by David Han Breakdown of academic impact, for papers by Satoru Nagashima Breakdown of academic impact, for papers by Dinko Rekić Breakdown of academic impact, for papers by Madelé van Dyk Breakdown of academic impact, for papers by Glynn Morrish Breakdown of academic impact, for papers by François A. Leblond Breakdown of academic impact, for papers by Melih O. Babaoğlu Breakdown of academic impact, for papers by Gunnar Ekenved Breakdown of academic impact, for papers by Amanda Freeman
Rankless by CCL
2026